<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01160419</url>
  </required_header>
  <id_info>
    <org_study_id>NEO-FLOT</org_study_id>
    <secondary_id>EudraCT Nr.: 2008-007546-56</secondary_id>
    <nct_id>NCT01160419</nct_id>
  </id_info>
  <brief_title>Multicenter Study to Perioperative Chemotherapy for Resectable Adenocarcinoma in Gastric Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <brief_summary>
    <textblock>
      The rationale of the NEO-FLOT-trial consists of an intensification of the neoadjuvant
      treatment.

      This strategy is based upon the clear advantage of perioperative treatment and the fact, that
      in former trials adjuvant treatment could only be given in half of the patients (Cunningham
      2006, Boige 2007).

      In this study neoadjuvant chemotherapy is applied during a period of 12 weeks with an interim
      staging after 6 weeks.Due to the favourable efficacy and toxicity data the FLOT-regimen was
      chosen for the neoadjuvant treatment consisting of oxaliplatin, docetaxel, folinic acid and
      5-Fluorouracil (Al-Batran 2008).

      Postoperative treatment according to the results of the MAGIC trail is not part of the trail
      and is given at the responsibility of the participating centres.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 2009</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Collection of the R0-Resection rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>after 6 cycles of biweekly FLOT chemotherapy and operation.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">49</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>FLOT</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Docetaxel, Oxaliplatin, Folinic acid, 5-FU, q 2 weeks, application of 6 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel 50 mg/m2, 1-hour-Infusion, day 1</intervention_name>
    <description>50 mg/m2, 1-hour-Infusion, day 1</description>
    <arm_group_label>FLOT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin 85 mg/m², 2-hour-Infusion, day 1</intervention_name>
    <description>85 mg/m², 2-hour-Infusion, day 1</description>
    <arm_group_label>FLOT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folinic acid 200 mg/m², 1-2-hour-Infusion, day 1</intervention_name>
    <description>200 mg/m², 1-2-hour-Infusion, day 1</description>
    <arm_group_label>FLOT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU 2600 mg/m², 24-hour-Infusion, day 1</intervention_name>
    <description>2600 mg/m², 24-hour-Infusion, day 1</description>
    <arm_group_label>FLOT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically Confirmed Adenocarcinoma of the Gastroesophageal Junction (AEG I-III)
             or Gastric Adenocarcinoma (every T, N+ or T3/T4, Nx, M0)

          -  Written Informed Consent

          -  Age ≥ 18 Years

          -  Expected operability

          -  ECOG ≤ 2

          -  Exclusion of Peritoneal Metastasis

          -  Adequate Hematological, Renal, Cardiac and Hepatic Function

          -  Effective Contraception

        Exclusion Criteria:

          -  Prior Chemotherapy or Radiotherapy of the Adenocarcinoma of the Gastroesophageal
             Junction (AEG I-III) or Gastric Adenocarcinoma

          -  Not Histologically Confirmed Primary Tumor

          -  Distant Metastasis, Local Relapse

          -  Known Hypersensitivity for 5-Fluorouracil, Leucovorin, Oxaliplatin or Docetaxel

          -  Known Dihydropyrimidin-Dehydrogenase (DPD) - Deficiency

          -  Peripheral Polyneuropathy ≥ Grade II (NCI-CTCAE, Version 3.0)

          -  Myocardial Infarction in the last 3 Months, Cardiac Insufficiency Grade II-IV (NYHA)

          -  Severe Comorbidity or Acute Infections

          -  Pregnancy or Breast Feeding

          -  Insufficient Contraception

          -  Participation in another Clinical Trial (Simultaneously or 30 Days Prior to
             Enrollment)

          -  Malignancy &lt;5 years (except: Carcinoma In Situ of the Cervix Uteri or Adequately
             Treated Basalioma of the Skin)

          -  Lack of Legal Capacity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Munich, Klinikum Grosshadern</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2009</study_first_submitted>
  <study_first_submitted_qc>July 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2010</study_first_posted>
  <last_update_submitted>October 27, 2010</last_update_submitted>
  <last_update_submitted_qc>October 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. med. V. Heinemann</name_title>
    <organization>University of Munich - Klinikum Großhadern</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

